Valuation: Relay Therapeutics, Inc.

Market Cap 402.12Cr 360.14Cr 331.27Cr 300.16Cr 561.08Cr 38TCr 571.58Cr 3.95TCr 1.59TCr 20TCr 1.51TCr 1.48TCr 63TCr P/E 2026 *
-11.4x
P/E 2027 * -11.4x
Enterprise Value 345.06Cr 309.03Cr 284.26Cr 257.56Cr 481.45Cr 33TCr 490.46Cr 3.39TCr 1.36TCr 17TCr 1.29TCr 1.27TCr 54TCr EV / Sales 2026 *
308x
EV / Sales 2027 * 200x
Free-Float
91.42%
Yield 2026 *
-
Yield 2027 * -
1 day-5.75%
1 week+0.94%
Current month+1.66%
1 month+1.66%
3 months-5.66%
6 months+41.59%
Current year+116.90%
1 week 17.82
Extreme 17.82
20.2
1 month 16.13
Extreme 16.13
20.2
Current year 7.01
Extreme 7.01
21.27
1 year 5.95
Extreme 5.95
21.27
3 years 1.78
Extreme 1.775
21.27
5 years 1.78
Extreme 1.775
37.52
10 years 1.78
Extreme 1.775
64.37
Manager TitleAgeSince
Chief Executive Officer 52 01/03/2017
Director of Finance/CFO 49 01/04/2018
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 54 04/05/2015
Director/Board Member 66 01/07/2016
Director/Board Member 52 01/03/2017
Date Insider Type Main position Quantity % Market Cap. Importance
07/10/26 Sell

Chief Executive Officer

-48,199 0.0220%
06/10/26 Sell

Chief Financial Officer

-17,717 0.0081%
08/09/26 Sell

Chief Financial Officer

-17,717 0.0081%
Change 5-day change 1-year change 3-year change Capi.($)
-5.75%+0.94%+150.00%+194.54% 402.12Cr
-0.62%-1.87%+46.31%+56.99% 6.38TCr
+0.35%+3.20%+14.92%+84.55% 5.64TCr
+0.53%+1.96%+15.37%+106.81% 5.46TCr
-2.81%-4.31%+23.50%+50.90% 4.41TCr
-0.33%-1.93%+20.15%+98.45% 4.21TCr
+0.55%+2.31%+224.97%+942.56% 4.1TCr
+3.27%+47.96%+112.67%+96.48% 3.49TCr
+1.22%-1.44%+14.89%+47.15% 3.28TCr
+0.89%+20.55%-42.03%+373.03% 2.47TCr
Average -0.27%+6.88%+58.07%+205.14% 3.98TCr
Weighted average by Cap. +0.12%+5.40%+49.53%+186.21%

Financials

2026 *2027 *
Net sales 1.12Cr 1Cr 92.14L 83.49L 1.56Cr 106.2Cr 1.59Cr 11Cr 4.41Cr 56Cr 4.2Cr 4.11Cr 176.18Cr 1.79Cr 1.6Cr 1.48Cr 1.34Cr 2.5Cr 170.08Cr 2.55Cr 18Cr 7.06Cr 89Cr 6.72Cr 6.58Cr 282.15Cr
Net income -32Cr -29Cr -26Cr -24Cr -45Cr -3.04TCr -46Cr -314.49Cr -126.25Cr -1.6TCr -120.14Cr -117.58Cr -5.04TCr -35Cr -31Cr -29Cr -26Cr -48Cr -3.3TCr -49Cr -341.21Cr -136.97Cr -1.73TCr -130.35Cr -127.58Cr -5.47TCr
Net Debt -57Cr -51Cr -47Cr -43Cr -80Cr -5.42TCr -81Cr -560.65Cr -225.06Cr -2.85TCr -214.18Cr -209.62Cr -8.99TCr -44Cr -40Cr -36Cr -33Cr -62Cr -4.2TCr -63Cr -434.22Cr -174.31Cr -2.21TCr -165.88Cr -162.35Cr -6.96TCr
Projected Income Statement - Annual - Relay Therapeutics, Inc.
Logo Relay Therapeutics, Inc.
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.
Employees
202
Date Price Change Volume
30/26/30 $18.35 -5.75% 35,96,210
29/26/29 $19.47 -1.12% 19,45,348
28/26/28 $19.69 +4.51% 28,08,741
27/26/27 $18.84 +3.97% 22,58,311
26/26/26 $18.12 -0.33% 15,85,748
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Relay Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
18.35USD
Average target price
27.58USD
Spread / Average Target
+50.32%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Relay Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. RLAY Stock